Lonza 4D-Nucleofector LV Unit for non-viral primary T-cell transfection

Saturday, 10 September, 2016 | Supplied by: Capsugel Australia Pty Ltd


Lonza has announced its 4D-Nucleofector LV Unit, the latest addition to the 4D-Nucleofector System, which expands non-viral primary T-cell transfection to a closed, larger-scale format. Nucleofector Technology is said to improve on traditional electroporation methods to deliver enhanced transfection efficiencies while using less substrate and with only a moderate impact on cell viability. It is suitable for scientists working with hard-to-transfect cell types, like primary blood cells or stem cells.

The system was designed with the scientist in mind, so transfection protocols established on the existing smaller-scale unit can be smoothly transferred to the large-scale unit without the need for re-optimisation. The fully closed system is also suitable for use in a regulatory environment as it can be controlled by 21 CFR Part 11-compatible software. The addition of this larger-scale transfection format allows scientists to translate the results of their research applications into potential therapeutic applications.

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Parse Biosciences Evercode Low Input Fixation kits for cells and nuclei

The kits empower researchers who have a small number of starting cells or nuclei who ordinarily...

EpigenTek MethylFlash Hydroxymethylated DNA Quantification Kit (Fluorometric)

The kit is a complete set of optimised buffers and reagents to fluorometrically quantify global...

siTOOLs Biotech raPOOLs RNA antisense pools

RNA antisense pools (raPOOLs), from siTOOLs Biotech, provide robust and specific isolation of...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd